HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Junghyun Kim Selected Research

KIOM 79

1/2013Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats.
1/2012KIOM-79 protects AGE-induced retinal pericyte apoptosis via inhibition of NF-kappaB activation in vitro and in vivo.
10/2011KIOM-79 inhibits aldose reductase activity and cataractogenesis in Zucker diabetic fatty rats.
4/2011Protection against advanced glycation end products and oxidative stress during the development of diabetic keratopathy by KIOM-79.
1/2011KIOM-79, an Inhibitor of AGEs-Protein Cross-linking, Prevents Progression of Nephropathy in Zucker Diabetic Fatty Rats.
1/2011KIOM-79 Prevents Lens Epithelial Cell Apoptosis and Lens Opacification in Zucker Diabetic Fatty Rats.
1/2011Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats.
6/2010KIOM-79 prevents methyglyoxal-induced retinal pericyte apoptosis in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Junghyun Kim Research Topics

Disease

17Diabetic Retinopathy (Retinopathy, Diabetic)
07/2020 - 06/2010
12Body Weight (Weight, Body)
11/2020 - 04/2011
12Diabetic Nephropathies (Diabetic Nephropathy)
01/2019 - 01/2010
11Type 2 Diabetes Mellitus (MODY)
12/2021 - 01/2011
10Hyperglycemia
01/2022 - 01/2011
10Retinal Neovascularization
06/2020 - 01/2013
9Obesity
04/2022 - 07/2009
9Diabetes Complications
03/2019 - 09/2009
8Albuminuria
01/2021 - 01/2010
7Neoplasms (Cancer)
08/2022 - 06/2017
6Cataract (Cataracts)
03/2016 - 06/2010
5Inflammation (Inflammations)
01/2020 - 01/2011
4Tuberculosis (Tuberculoses)
11/2020 - 01/2016
4Macular Degeneration (Age-Related Maculopathy)
06/2020 - 01/2013
4Chronic Renal Insufficiency
10/2019 - 08/2013
3Dry Eye Syndromes (Dry Eye Syndrome)
05/2022 - 11/2016
3Choroidal Neovascularization
01/2022 - 11/2015
3Diarrhea
12/2021 - 01/2002
3Infections
06/2020 - 01/2016
3Vascular System Injuries
04/2019 - 01/2013
3Proteinuria
10/2015 - 01/2010
2Weight Gain
04/2022 - 11/2020
2Insulin Resistance
01/2022 - 11/2020
2Stroke (Strokes)
10/2021 - 04/2020
2Latent Tuberculosis
11/2020 - 06/2020
2Breast Neoplasms (Breast Cancer)
11/2020 - 06/2018
2Fibrosis (Cirrhosis)
10/2020 - 01/2013
2Hyperoxia
06/2020 - 01/2020
2Atherosclerosis
04/2020 - 10/2019
2Heart Failure
04/2020 - 09/2012
2Pulmonary Tuberculosis
01/2019 - 01/2016
2Pneumonia (Pneumonitis)
12/2018 - 01/2016
2Chronic Obstructive Pulmonary Disease (COPD)
01/2017 - 01/2016
2Hemorrhage
07/2013 - 10/2010
2Rupture
01/2013 - 05/2011
2Acute Kidney Injury (Acute Renal Failure)
08/2012 - 10/2010
2Wasting Syndrome (Wasting Disease)
07/2009 - 05/2003
1Salivary Gland Neoplasms (Salivary Gland Cancer)
08/2022

Drug/Important Bio-Agent (IBA)

24Retinaldehyde (Retinal)IBA
07/2020 - 06/2010
16Advanced Glycation End ProductsIBA
07/2020 - 09/2009
11Pharmaceutical PreparationsIBA
08/2022 - 01/2012
10Blood Glucose (Blood Sugar)IBA
11/2020 - 01/2010
9Proteins (Proteins, Gene)FDA Link
08/2022 - 06/2010
8KIOM 79IBA
01/2013 - 06/2010
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2020 - 03/2015
6DNA (Deoxyribonucleic Acid)IBA
01/2022 - 05/2003
5Messenger RNA (mRNA)IBA
01/2022 - 06/2010
5Lipase (Acid Lipase)FDA Link
11/2020 - 07/2009
5Oxygen (Dioxygen)IBA
06/2020 - 11/2014
5Plant ExtractsIBA
03/2019 - 01/2010
5Aldehyde Reductase (Aldose Reductase)IBA
03/2016 - 05/2011
4aucubinIBA
05/2022 - 10/2018
4Ethanol (Ethyl Alcohol)IBA
11/2020 - 03/2019
4LC15-0444IBA
10/2016 - 12/2014
4HMGB1 Protein (HMG1)IBA
10/2016 - 01/2011
4Galactose (Galactopyranose)FDA LinkGeneric
03/2016 - 05/2011
3GS-E3DIBA
01/2021 - 08/2017
3LipidsIBA
11/2020 - 07/2009
3EnzymesIBA
11/2020 - 01/2013
3Radioisotopes (Radionuclides)IBA
12/2017 - 06/2017
3Streptozocin (Streptozotocin)FDA Link
03/2016 - 01/2010
3SugarsIBA
03/2016 - 05/2011
3NF-kappa B (NF-kB)IBA
02/2012 - 06/2010
2esculetinIBA
08/2022 - 03/2016
2Particulate MatterIBA
05/2022 - 02/2019
2Phosphotransferases (Kinase)IBA
04/2022 - 01/2009
2gamma-Aminobutyric Acid (GABA)IBA
04/2022 - 01/2021
2Antisense OligonucleotidesIBA
01/2022 - 10/2020
2Small Interfering RNA (siRNA)IBA
12/2021 - 01/2020
2Immunoglobulin A (IgA)IBA
11/2020 - 06/2020
2Immunoglobulin G (IgG)IBA
11/2020 - 06/2020
2Monoclonal AntibodiesIBA
11/2020 - 07/2009
2SteroidsIBA
09/2020 - 01/2016
2OccludinIBA
07/2020 - 03/2015
2Biomarkers (Surrogate Marker)IBA
04/2020 - 01/2018
2Glucose (Dextrose)FDA LinkGeneric
04/2019 - 01/2018
2Matrix Metalloproteinases (MMPs)IBA
02/2019 - 12/2018
2Therapeutic UsesIBA
10/2018 - 11/2016
2Dipeptidyl-Peptidase IV InhibitorsIBA
10/2016 - 08/2015
2Receptor for Advanced Glycation End ProductsIBA
10/2016 - 01/2011
2butylidenephthalideIBA
07/2016 - 11/2015
2Becaplermin (PDGF-BB)FDA Link
12/2014 - 11/2014
2Cisplatin (Platino)FDA LinkGeneric
08/2012 - 10/2010
2AcidsIBA
01/2011 - 01/2010
2Formaldehyde (Formol)FDA Link
07/2009 - 05/2003
2ParaffinIBA
07/2009 - 05/2003
1BromidesIBA
08/2022
1Ophthalmic Solutions (Eye Drops)IBA
05/2022
1AntioxidantsIBA
04/2022
1Amino AcidsFDA Link
04/2022
1EndoribonucleasesIBA
04/2022
1Sirtuin 1IBA
04/2022
1Inositol (Myoinositol)IBA
04/2022
1Protein CoronaIBA
01/2022
1Sweetening Agents (Sweeteners)IBA
01/2022

Therapy/Procedure

7Therapeutics
01/2022 - 10/2016
3Oral Administration
08/2017 - 03/2016
2Lasers (Laser)
01/2022 - 11/2015
2Critical Care (Surgical Intensive Care)
01/2021 - 01/2016
2Lenses
02/2012 - 10/2011